Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 3939-3945

  Henz, Samuel ^a   Maeder, Micha T ^a   Huber, Stephanie ^b   Schmid, Michael ^b   Loher, Marcel ^b   Fehr, Thomas ^c  

^a Kantonsspital ^*  (Switzerland)

^b FHO Fachhochschule Ostschweiz   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse drug effects; Hyperkalaemia; Hypokalaemia; Pharmacoepidemiology; Potassium

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; HEPARIN; LAXATIVE; LEVODOPA; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; TACROLIMUS; THEOPHYLLINE; THIAZIDE DIURETIC AGENT;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIARRHEA; DRUG EFFECT; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENDER; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SWITZERLAND;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; COHORT STUDIES; COMORBIDITY; DIURETICS; DRUG INTERACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LAXATIVES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; POTASSIUM; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 56749163650     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn380     Document Type: Article

References (33)

1. Halperin M, Kamel K. Electrolyte quintet: potassium. Lancet 1998; 352: 135-140
2. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004; 43: 155-161
3. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592
4. Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-1315
5. Kamel K, Halperin M, Faber M et al. Disorders of potassium balance. In: Brenner B. (ed.). Brenner and Rector's the Kidney, 5th edn. Philadelphia: Saunders, 1996, 999-1037
6. Gennari FJ. Hypokalemia. N Engl J Med 1998; 339: 451-458
7. WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. World Health Organisation http://www.whocc.no/ atcddd/
8. Stevens LA, Coresh J, Greene T et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483
9. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310
10. Ellison DH. Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. Am J Physiol Renal Physiol 2000; 279: F616-F625
11. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-395
12. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007; 356: 1966-1978
13. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
15. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771
16. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675
17. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158: 26-32
18. Bakris GL, Siomos M, Richardson D et al. VAL-K Study Group. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000; 58: 2084-2092
19. Gansevoort RT, van Veldhuisen DJ. Comparison of losartan and captopril in ELITE II. Lancet 2000; 356: 851-852
20. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124
21. Pitt B, Zannad F, Remme WJ et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
22. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551
23. Wrenger E, Muller R, Moesenthin M et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147-149
24. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003; 18: 1814-1819
25. Kaplan B, Wang Z, Abecassis MM et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996; 62: 1174-1175
26. Kamel KS, Ethier JH, Quaggin S et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1992; 2: 1279-1284
27. Caliskan Y, Kalayoglu-Besisik S, Sargin D et al. Cyclosporine-associated hyperkalemia: report of four allogenic blood stem-cell transplant cases. Transplantation 2003; 75: 1069-1072
28. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med 1989; 110: 426-429
29. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant 2003; 18: 2215-2218
30. Grove A, McFarlane LC, Lipworth BJ. Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995; 50: 134-138
31. Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. Pharmacology 1993; 47(Suppl 1): 138-145
32. Psaty BM, Burke SP. Protecting the health of the public - Institute of Medicine recommendations on drug safety. N Engl J Med 2006; 355: 1753-1755
33. Avorn J. Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med 2006; 355: 2169-2211